Clinical trial
Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma
NCT00243035 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00243035 |
|---|---|
| Title | Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma |
| Official title | A Dose Escalation Study of R115777 (Zarnestra) Combined With Velcade® (PS-341) in Patients With Relapsed Multiple Myeloma. |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma |
| Intervention type | Drug, Other |
| Interventions | bortezomib, tipifarnib, laboratory biomarker analysis |
| Enrollment | 64 |
| Start date | Aug 1, 2005 |
| Primary completion | Feb 1, 2007 |
| First posted | Oct 21, 2005 |
| Last update posted | Oct 8, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: